Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(16):1188-1191; doi:10.1093/jnci/90.16.1188
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jenks, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jenks, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

R. Michael Blaese: Still Blazing a Path Of His Own

Reports of his imminent departure, it seems, have been greatly exaggerated. Nearly 7 months after being named chief scientific officer and president of the Molecular Pharmaceuticals Division of a small Pennsylvania biotech company, R. Michael Blaese, M.D. -- one of the world's leading gene therapists -- is still on the National Institutes of Health campus, still a federal employee, and still ensconced in his scenic 10th floor office at the NIH clinical center.


But Blaese, chief of the Clinical Gene Therapy Branch at the National Human Genome Research Institute, according to his own "working plan," will move over to Kimeragen, Inc., in Newtown, Pa., in the next few months, while staying involved in clinical protocols at the NIH for at least another year.

Strong Ties

Then who knows? Something in his manner suggests that after 32 years at the NIH, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?